Navigation Links
Questcor to Commence Phase 2 Study of Acthar for ALS
Date:7/24/2013

ANAHEIM, Calif., July 24, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that patient screening will commence in connection with Questcor's Phase 2 Study to explore the safety and tolerability of H.P. Acthar® Gel (repository corticotropin injection) in patients with Amyotrophic Lateral Sclerosis (ALS).  ALS -- often referred to as Lou Gehrig's disease -- is a progressive, degenerative disease affecting motor neurons.  ALS is a serious debilitating disease that significantly alters one's quality of life.  According to the ALS Association, the average life expectancy from the time of diagnosis for someone affected by this disorder is about two to five years.

The study will seek to enroll up to 40 patients in an 8-week randomized, open-label trial designed to explore the safety and tolerability of four dosing regimens of Acthar.  Patients who successfully conclude the initial 8-week trial will then have the option to participate in a 28-week open-label extension with a 3-week taper and one week follow-up period.  The study will also examine whether Acthar provides any functional improvement to ALS patients.

"Questcor has focused its expanding R&D efforts on devastating medical conditions for which patients are in need of new treatment options," said Dr. David Young, Questcor's Chief Scientific Officer. " We are continually understanding more about the mechanism of action of Acthar and how it might provide benefit to patients in need.  Initial non-clinical research efforts provided us with data suggesting that Acthar may potentially provide therapeutic benefit to patients with ALS, leading us to conduct this important phase 2 study to further explore this possibility."

"In a
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Questcor to Report Second Quarter Financial Results on July 30, 2013
2. Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis
3. Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
4. Questcor Adds Angus C. Russell to Board of Directors
5. Questcor Reports First Quarter Financial Results
6. Questcor to Report First Quarter Results on April 30, 2013
7. Questcor Reports Fourth Quarter and Full Year 2012 Results
8. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
9. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
10. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
11. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... N.J. , Nov. 21, 2014  PTC Therapeutics, Inc. ... the 2014 Legend of Technology Award for Vision, Innovation, and ... Ph.D., Chief Executive Officer. This award recognizes an individual who ... New Jersey for several decades. ... Technology Award," stated Stuart Peltz , Ph.D., CEO of ...
(Date:11/21/2014)... and MELVILLE, N.Y. , Nov. 21, ... ), one of the world,s largest health care services ... ), the world,s largest provider of health care products ... practitioners, today announced that the companies have entered into ... most comprehensive service and product offerings to office-based medical ...
(Date:11/21/2014)... 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) ... Officer, will be presenting at the 26 th Annual ... in New York . The formal presentation ... ET. In addition, Mr. Krakauer and Jorgen B. Hansen ... meetings during the day. An audio webcast ...
Breaking Medicine Technology:PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5
... Johnson & Johnson Pharmaceutical,Research & Development, ... demonstrate doripenem (DORIBAX(TM), doripenem for injection), a,carbapenem ... in vitro against certain,strains of Enterobacteriaceae, including ... Enterobacteriaceae is a large group of ...
... annual ICAAC/IDSA meeting in Washington, D.C., WASHINGTON, ... nail,fungus, NB-002, has demonstrated a new topical approach ... diffusing through the skin that,surrounds the entire nail ... The data represent a unique approach to ...
Cached Medicine Technology:New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 2New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 3New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 4New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 5NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy 2NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy 3
(Date:11/23/2014)... 23, 2014 Today Zane Benefits, ... small businesses, announced their new on demand webinar ... Employer-Provided Health Insurance. , According to ... financial risk facing most American families. It is ... and large, when it comes to recruiting and ...
(Date:11/22/2014)... Recently, UWDress.com, a successful wedding dress shop, has ... in order to prepare for the wedding season. All ... off. , UWDress.com is a reliable company that has ... the new items -- formal wedding guest attire. This new ... including superstar and princess. As one of the leading companies ...
(Date:11/22/2014)... NY (PRWEB) November 22, 2014 ... Goods Administration (TGA) approved it for use “as ... approved and listed within the Therapeutic Goods (Listing) ... , Kyowa Hakko’s Setria® Glutathione will be ... biotech specialist that sources and imports fine chemicals ...
(Date:11/22/2014)... November 22, 2014 "My friend went ... caused by the machine," said an inventor from Cambria ... to go back a second time because the first ... , She developed the patent-pending MAMO EASY to offer ... The design saves the patient from the pain normally ...
(Date:11/22/2014)... York (PRWEB) November 22, 2014 Lipitor ... behalf of patients who allegedly developed Type 2 diabetes ... the federal multidistrict litigation now underway in U.S. District ... According to court documents, the litigation will convene its ... The Court has directed Lead Counsel for Plaintiffs and ...
Breaking Medicine News(10 mins):Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3
... finds people who participated in a cardiac-rehab program after a ... as those of the same age and sex who had ... of the deaths that occurred among patients in their study ... ,The investigation involved about 1,800 patients. Nearly 60 percent ...
... low-glycemic index diet can lead to weight loss, reduced ... and cardiovascular disease. In low-GI foods, carbohydrates are low ... include white bread, refined breakfast cereals and concentrated sugars, ... to high levels. Carbs that release sugar more slowly ...
... A new study shows consuming foods or supplements containing the ... way to avoid Alzheimer’s disease // even if you carry ... the study researchers first bred mice to carry the gene ... Initially various environmental factors affecting the symptoms were studied but ...
... at an increased risk of dying from heart disease. ... more traits of metabolic syndrome have a 3.5-times higher ... syndrome is a group of metabolic risk factors including ... disorders, insulin resistance or glucose intolerance, and high-normal blood ...
... Mental decline usually associated with age, might affect women ... according to a recent study .// ,The ... worse cognitive performance and are at an increased risk ... cognitive impairment among women with pre-diabetes or diabetes was ...
... the number of Americans living with high blood pressure has ... pressure is defined // as having blood pressure of 140/90 ... their doctors at least twice that their blood pressure is ... ,However researchers say the study did not examine the reasons ...
Cached Medicine News:
The Gizmo male external catheter is a latex catheter that uses a single-sided adhesive strip....
... The Mentor Freedom Pak Seven ... packaged week's supply of Freedom ... kit all 100% latex-free ... wipes for your convenience and ...
Clear Advantage® is a premium 100% latex-free, self-adhering, one-piece catheter designed for maximum wear. It features aloe in the adhesive, and a kink-resistant nozzle designed to eliminate blo...
... all-silicone non-adhesive male external catheter is ... latex-related allergic reactions. It is designed ... change external catheters several times a ... catheter comes with an adjustable strap ...
Medicine Products: